Published on 12 May 2022 on Zacks via Yahoo Finance
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug
Regulus Therapeutics Inc. RGLS announced that the FDA has accepted the investigational new drug (“IND”) application for its novel pipeline candidate, RGLS8429, seeking approval to begin clinical studies on the same for the treatment of autosomal dominant polycystic kidney disease (“ADPKD”).
The company plans to initiate a phase I study evaluating RGLS8529 in healthy volunteers for treating ADPKD later in the second quarter of 2022.
Shares of Regulus were up 54.8% following the announcement of the news on Wednesday. The stock has lost 15.6% so far this year compared with the industry’s decline of 26.8%.